Compare Dr. Reddys with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PIRAMAL ENTERPRISES - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PIRAMAL ENTERPRISES DR. REDDYS LAB/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 21.5 15.5 138.6% View Chart
P/BV x 3.2 1.0 326.6% View Chart
Dividend Yield % 0.7 1.8 40.8%  

Financials

 DR. REDDYS LAB   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
PIRAMAL ENTERPRISES
Mar-19
DR. REDDYS LAB/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2,8753,303 87.1%   
Low Rs1,8881,797 105.1%   
Sales per share (Unadj.) Rs930.2716.5 129.8%  
Earnings per share (Unadj.) Rs117.479.7 147.3%  
Cash flow per share (Unadj.) Rs185.8107.9 172.1%  
Dividends per share (Unadj.) Rs20.0028.00 71.4%  
Dividend yield (eoy) %0.81.1 76.5%  
Book value per share (Unadj.) Rs844.41,477.5 57.2%  
Shares outstanding (eoy) m166.07184.45 90.0%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.63.6 71.9%   
Avg P/E ratio x20.332.0 63.4%  
P/CF ratio (eoy) x12.823.6 54.3%  
Price / Book Value ratio x2.81.7 163.4%  
Dividend payout %17.035.1 48.5%   
Avg Mkt Cap Rs m395,496470,292 84.1%   
No. of employees `00022.07.8 280.9%   
Total wages/salary Rs m33,56222,504 149.1%   
Avg. sales/employee Rs Th7,032.816,899.4 41.6%   
Avg. wages/employee Rs Th1,527.92,877.7 53.1%   
Avg. net profit/employee Rs Th887.71,879.9 47.2%   
INCOME DATA
Net Sales Rs m154,482132,153 116.9%  
Other income Rs m3,3753,128 107.9%   
Total revenues Rs m157,857135,281 116.7%   
Gross profit Rs m31,78266,290 47.9%  
Depreciation Rs m11,3485,202 218.2%   
Interest Rs m88944,097 2.0%   
Profit before tax Rs m22,92020,119 113.9%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8588,611 44.8%   
Profit after tax Rs m19,50014,701 132.6%  
Gross profit margin %20.650.2 41.0%  
Effective tax rate %16.842.8 39.3%   
Net profit margin %12.611.1 113.5%  
BALANCE SHEET DATA
Current assets Rs m111,101122,742 90.5%   
Current liabilities Rs m58,973310,810 19.0%   
Net working cap to sales %33.7-142.3 -23.7%  
Current ratio x1.90.4 477.1%  
Inventory Days Days7923 344.0%  
Debtors Days Days9439 242.5%  
Net fixed assets Rs m101,245116,904 86.6%   
Share capital Rs m830369 225.0%   
"Free" reserves Rs m139,406272,161 51.2%   
Net worth Rs m140,236272,530 51.5%   
Long term debt Rs m22,000270,196 8.1%   
Total assets Rs m224,656856,261 26.2%  
Interest coverage x26.81.5 1,839.1%   
Debt to equity ratio x0.21.0 15.8%  
Sales to assets ratio x0.70.2 445.5%   
Return on assets %9.16.9 132.2%  
Return on equity %13.95.4 257.8%  
Return on capital %14.912.4 120.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67315,200 583.4%   
Fx outflow Rs m19,1044,889 390.8%   
Net fx Rs m69,56910,312 674.7%   
CASH FLOW
From Operations Rs m28,704-115,975 -24.8%  
From Investments Rs m-7,727-8,265 93.5%  
From Financial Activity Rs m-21,326107,525 -19.8%  
Net Cashflow Rs m-314-16,650 1.9%  

Share Holding

Indian Promoters % 25.5 52.9 48.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.0 135.0%  
FIIs % 35.3 26.6 132.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 16.5 92.7%  
Shareholders   75,885 93,274 81.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SUVEN LIFESCIENCES  SHASUN PHARMA  NOVARTIS  TTK HEALTHCARE  SUN PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 18, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - SUN PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS